'Heeding Kennedy's Wishes, F.D.A. Is Expected to Lift Restriction on Peptides'- New York Times

The FDA is expected to lift restrictions on peptides, aligning with the wishes of Robert F. Kennedy Jr. This regulatory change could significantly impact the peptide market and related companies, including HIMS. The anticipated decision may lead to increased opportunities for growth and innovation in peptide therapies.